Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients

Table 6 Summary of controlled attenuation parameter score in norursodeoxycholic acid and placebo groups at different time points

Visit	norUDCA		Placebo		P value	Change from baseline (P value)
	n	mean ± SD	n	mean ± SD
Baseline	72	276.21 ± 47.56	38	271.74 ± 39.04	0.62
Visit 4/week 12	72	243.40 ± 45.14	38	261.78 ± 50.4	0.054	0.003
Visit 6/week 24	72	228.04 ± 45.69	38	246.10 ± 42.74	0.014	0.005

Means are represented in dB/m. norUDCA: Norursodeoxycholic acid.